From Dealroom · · 50s
4Tissue raises €7M for resorbable breast implant trials
4Tissue gets €7.8m to test dissolving breast implants in humans.
In brief
4Tissue gets €7.8m to test dissolving breast implants in humans. 4Tissue raised €7 million to begin first-in-human testing of a resorbable breast implant designed to break down inside the body. Originally reported by Dealroom.
Quick answers
- What's the deal?
- Ghent-based biotech 4Tissue has raised €7 million ($7.8 million) to begin first-in-human testing of a breast implant designed to break down inside the body.
- What's the endgame?
- 4Tissue is developing an injectable approach that combines a hydrogel scaffold with cells to help a patient's own tissue grow, then dissolves leaving natural tissue.
- Why now?
- The raise moves the concept from lab to clinical evaluation, with human testing marking the next milestone for an alternative to permanent implants and flap surgery.
- What is the key takeaway from 4Tissue raises €7M for resorbable breast implant trials?
- 4Tissue raised €7 million to begin first-in-human testing of a resorbable breast implant designed to break down inside the body.
What's the deal?
Ghent-based biotech 4Tissue has raised €7 million ($7.8 million) to begin first-in-human testing of a breast implant designed to break down inside the body.
What's the endgame?
4Tissue is developing an injectable approach that combines a hydrogel scaffold with cells to help a patient's own tissue grow, then dissolves leaving natural tissue.
Why now?
The raise moves the concept from lab to clinical evaluation, with human testing marking the next milestone for an alternative to permanent implants and flap surgery.
What to remember
4Tissue raised €7 million to begin first-in-human testing of a resorbable breast implant designed to break down inside the body.
